Original Article

European Journal of Pediatrics

, Volume 172, Issue 1, pp 39-43

First online:

A disease severity scoring system for children with type 1 Gaucher disease

  • Staci KallishAffiliated withDivision of Genetics and Metabolism, Department of Pediatrics, Floating Hospital for Children at Tufts Medical Center
  • , Paige KaplanAffiliated withChildren’s Hospital of PhiladelphiaDivision of Metabolism, Children’s Hospital of Philadelphia Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Almost half of patients with Gaucher disease are diagnosed by the age of 10 years, and approximately two thirds are diagnosed by the age of 20 years. Besides symptomatic children, some presymptomatic children are being diagnosed through community screening programs and because of affected siblings. In addition, it is anticipated that in the near future, newborn screening for lysosomal diseases such as Gaucher disease will be introduced in the USA, identifying additional pre/nonsymptomatic children. Currently, there is no severity scoring system for children. A validated disease severity scoring system in the pediatric Gaucher population will be essential for classifying disease severity in these children, monitoring their disease progression, making decisions about when to treat them, and monitoring disease improvement with therapy. A severity scoring system will also be helpful in comparing therapeutic options as new therapies are designed. Therefore, a Pediatric Gaucher Severity Scoring System (PGS3) was devised using expert opinion and validated in 26 patients with type 1 Gaucher disease. The PGS3 correlates well with disease severity in patients at diagnosis and over time. Conclusion: A practical system that will help clinical management, based on signs and symptoms in children with type 1 Gaucher disease, is presented.


Pediatric Gaucher disease Severity score Lysosomal storage disease Enzyme replacement therapy